Effects of 24 Weeks of Growth Hormone Treatment on Bone Microstructure and Volumetric Bone Density in Patients with Childhood-Onset Adult GH Deficiency
Table 3
Baseline and follow-up HR-pQCT parameters of the distal tibia.
Baseline
24-week follow-up
Changes
value
Total vBMD (mg HA/cm3)
200.2 ± 41.7
210.3 ± 40.9
10.01 ± 10.11
0.017
Cortical area (mm2)
89.9 ± 17.7
95.5 ± 19.9
5.60 ± 6.47
0.032
Cortical vBMD (mg HA/cm3)
870.3 ± 53.2
857.4 ± 60.0
8.60 (−78.60, 21.00)
0.311
Cortical perimeter (mm)
114.0 ± 14.3
114.4 ± 14.2
0.33 ± 0.64
0.157
Cortical thickness (mm)
0.891 ± 0.197
0.944 ± 0.239
0.05 ± 0.07
0.028
Intracortical porosity
0.008 ± 0.003
0.010 ± 0.005
0.001 (−0.001, 0.009)
0.094
Trabecular area (mm2)
795.3 ± 280.9
789.6 ± 211.4
−5.71 ± 6.44
0.029
Trabecular vBMD (mg HA/cm3)
121.6 ± 29.4
128.0 ± 23.0
6.37 ± 10.20
0.098
Trabecular thickness (mm)
0.245 ± 0.034
0.248 ± 0.033
0.003 ± 0.011
0.482
Trabecular number (1/mm)
1.203 ± 0.318
1.253 ± 0.311
0.012 (−0.020, 0.219)
0.102
Trabecular separation (mm)
0.878 ± 0.295
0.841 ± 0.269
−0.004 (−0.250, 0.014)
0.227
Tb.1/N.SD (mm)
0.396 (0.199, 0.964)
0.389 (0.193, 0.995)
0.001 (−0.108, 0.031)
0.597
Trabecular bone volume fraction
0.193 ± 0.038
0.198 ± 0.036
0.004 ± 0.005
0.027
Data are presented as mean ± SD or median and ranges. vBMD, volumetric bone mineral density; Tb.1/N.SD, Std. dev. of 1/Tb.N, inhomogeneity of network.
